These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 10102467

  • 1. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
    Millet J, Jouault SC, Mauray S, Theveniaux J, Sternberg C, Boisson Vidal C, Fischer AM.
    Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W, Siekmeier R.
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ.
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [Abstract] [Full Text] [Related]

  • 6. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW, Thomas DP.
    Acta Chir Scand Suppl; 1988 Apr; 543():57-64. PubMed ID: 2847459
    [Abstract] [Full Text] [Related]

  • 7. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D, Dawes J.
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [Abstract] [Full Text] [Related]

  • 8. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Feb; 116(6):967-80. PubMed ID: 2483715
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F.
    Thromb Haemost; 1988 Jun 16; 59(3):388-91. PubMed ID: 2847348
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique.
    Millet J, Theveniaux J, Tachon G, Bogaievsky Y, Grippat JC, Samama M, Brown NL.
    Thromb Haemost; 1996 Dec 16; 76(6):989-92. PubMed ID: 8972022
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y.
    Thromb Haemost; 1995 Nov 16; 74(5):1286-92. PubMed ID: 8607111
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.